158 related articles for article (PubMed ID: 36178950)
21. The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure.
Gagno S; Buonadonna A; Dalle Fratte C; Guardascione M; Zanchetta M; Posocco B; Orleni M; Canil G; Roncato R; Cecchin E; Toffoli G
Daru; 2023 Dec; 31(2):267-272. PubMed ID: 37318715
[TBL] [Abstract][Full Text] [Related]
22. Impact of
Dalle Fratte C; Polesel J; Gagno S; Posocco B; De Mattia E; Roncato R; Orleni M; Puglisi F; Guardascione M; Buonadonna A; Toffoli G; Cecchin E
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834713
[TBL] [Abstract][Full Text] [Related]
23. Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP.
Tan ML; Yoshida K; Zhao P; Zhang L; Nolin TD; Piquette-Miller M; Galetin A; Huang SM
Clin Pharmacol Ther; 2018 May; 103(5):854-867. PubMed ID: 28990182
[TBL] [Abstract][Full Text] [Related]
24. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
25. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
26. Assessment of CYP2C9, CYP2C19, and CYP2D6 Polymorphisms in Allergic Patients with Chemical Sensitivity.
D'Attis S; Massari S; Mazzei F; Maio D; Vergallo I; Mauro S; Minelli M; Bozzetti MP
Int Arch Allergy Immunol; 2019; 179(3):173-186. PubMed ID: 30943525
[TBL] [Abstract][Full Text] [Related]
27. Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals.
Yin SJ; Qi HM; Wang X; Zhang P; Lu Y; Wei MJ; Li P; Qi GZ; Lou YQ; Lu C; Zhang GL
Pharmacogenet Genomics; 2017 Apr; 27(4):125-134. PubMed ID: 28099407
[TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
[TBL] [Abstract][Full Text] [Related]
29. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
30. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.
Skadrić I; Stojković O
Int J Legal Med; 2020 Mar; 134(2):433-439. PubMed ID: 31858263
[TBL] [Abstract][Full Text] [Related]
31. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Roots I; Brockmöller J
Pharmacogenetics; 2002 Oct; 12(7):571-80. PubMed ID: 12360109
[TBL] [Abstract][Full Text] [Related]
32. Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients.
Liu J; Chen Z; Chen H; Hou Y; Lu W; He J; Tong H; Zhou Y; Cai W
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335376
[TBL] [Abstract][Full Text] [Related]
33. Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes.
Nebot N; Crettol S; d'Esposito F; Tattam B; Hibbs DE; Murray M
Br J Pharmacol; 2010 Nov; 161(5):1059-69. PubMed ID: 20977456
[TBL] [Abstract][Full Text] [Related]
34. Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population.
Céspedes-Garro C; Rodrigues-Soares F; Jiménez-Arce G; Naranjo MG; Tarazona-Santos E; Fariñas H; Barrantes R; Llerena A;
Rev Biol Trop; 2016 Sep; 64(3):1067-76. PubMed ID: 29461783
[TBL] [Abstract][Full Text] [Related]
35. Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib.
Khan MS; Barratt DT; Somogyi AA
Xenobiotica; 2016; 46(3):278-87. PubMed ID: 26161459
[TBL] [Abstract][Full Text] [Related]
36. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
[TBL] [Abstract][Full Text] [Related]
37. Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.
Ricardo-Silgado ML; Singh S; Cifuentes L; Decker PA; Gonzalez-Izundegui D; Moyer AM; Hurtado MD; Camilleri M; Bielinski SJ; Acosta A
BMC Med; 2022 Jul; 20(1):261. PubMed ID: 35879764
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetic prediction of individual variability in drug response based on CYP2D6, CYP2C9 and CYP2C19 genetic polymorphisms.
Chaudhry SR; Muhammad S; Eidens M; Klemm M; Khan D; Efferth T; Weisshaar MP
Curr Drug Metab; 2014; 15(7):711-8. PubMed ID: 25429673
[TBL] [Abstract][Full Text] [Related]
39. Association of Hepatic Nuclear Factor 4 Alpha Gene Polymorphisms With Free Imatinib Plasma Levels and Adverse Reactions in Chinese Gastrointestinal Stromal Tumor Patients.
Chen H; Liu J; Zhou Y; Hou Y; Ma G; Cai W
Ther Drug Monit; 2019 Oct; 41(5):582-590. PubMed ID: 31045869
[TBL] [Abstract][Full Text] [Related]
40. LC-MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 and P-glycoprotein probe substrates and their metabolites using subtherapeutic doses.
Cusinato DAC; Filgueira GCO; Rocha A; Cintra MACT; Lanchote VL; Coelho EB
J Pharm Biomed Anal; 2019 Feb; 164():430-441. PubMed ID: 30445356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
